Account
Payers' valuation of the cost per month of overall survival
Publications

ISPOR 2015 Payers’ valuation of the cost per month of overall survival

11/11/2015

Do payers equally value the cost per month of overall survival for metastatic castration resistant prostate cancer with the EU5?

There have been several recent pharma product launches for the treatment of metastatic castration resistant prostate cancer (mCRPC). The aim of this study was to assess the launch price of mCRPC treatments across the EU5 (France, Germany, Italy, Spain, UK) in relation to a standard clinical measure, overall survival (OS), to determine if payers equally value the cost per OS month for mCRPC treatments. Furthermore, the cost per month of additional OS benefit versus comparator was assessed. An analysis of cost/survival for prostate cancer treatments has been previously conducted in the US.

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.